www.Cancer.gov News Releases

February 20, 2011 by  
Filed under Cancer in the news

http://www.cancer.gov/newscenter
  1. New approach to immunotherapy leads to complete response in breast cancer patient unresponsive to other treatments -

    A novel approach to immunotherapy developed by NCI researchers has led to the complete regression of breast cancer in a patient who was unresponsive to all other treatments. The findings were published in Nature Medicine.

  2. NCI-MATCH precision medicine clinical trial releases new findings, strengthens path forward for targeted cancer therapies -

    The NCI-MATCH precision medicine clinical trial has reached a milestone with the release of results from several study treatment arms. Findings from three arms were released at the 2018 ASCO annual meeting, adding to findings from one arm released in 2017.

  3. TAILORx trial finds most women with early breast cancer do not benefit from chemotherapy -

    Findings from the TAILORx clinical trial show chemotherapy does not benefit most women with early breast cancer. The new data, released at the 2018 ASCO annual meeting, will help inform treatment decisions for many women with early-stage breast cancer.

  4. NCI study finds gut microbiome can control antitumor immune function in liver -

    An NCI study in mice that found a connection between gut bacteria and antitumor immune responses in the liver has implications for understanding mechanisms that lead to liver cancer and for potential treatments. The study was published in Science.

  5. Annual Report to the Nation: overall cancer mortality continues to decline, prostate cancer mortality has stabilized -

    The 2018 Annual Report to the Nation on the Status of Cancer finds overall cancer death rates continue to decline and cancer incidence dropped in men and remained stable in women. A companion study reports on recent changes in prostate cancer trends.

  6. NCI study revises molecular classification for most common type of lymphoma -

    In a study in The New England Journal of Medicine, NCI researchers identified genetic subtypes of diffuse large B-cell lymphoma (DLBCL), the most common type of lymphoma, that could help explain why some patients with the disease respond to treatment and others don’t.

  7. NIH completes in-depth genomic analysis of 33 cancer types -

    The Cancer Genome Atlas (TCGA), supported by NIH’s NHGRI and NCI, concludes with an in-depth genomic analysis of 33 cancer types called the PanCancer Atlas. Findings are being published as a collection of 27 papers across multiple Cell journals.

  8. NIH-funded study shows sorafenib improves progression-free survival for patients with rare sarcomas -

    Interim results from a clinical trial for patients with desmoid tumors or aggressive fibromatosis (DT/DF) show that the drug sorafenib tosylate (Nexavar) extended progression-free survival compared with a placebo.

  9. Szent-Györgyi Prize to honor NCI’s Douglas R. Lowy and John T. Schiller -

    Dr. Douglas R. Lowy and Dr. John T. Schiller of the National Cancer Institute will receive the 2018 Szent-Gyorgyi Prize for Progress in Cancer Research for the development of HPV vaccines.

  10. Norman Sharpless sworn in as director of the National Cancer Institute -

    Norman E. “Ned” Sharpless, M.D., becomes the 15th director of the National Cancer Institute (NCI). He comes to NCI from the University of North Carolina School of Medicine, where he was director of the Lineberger Comprehensive Cancer Center.

Enter Google AdSense Code Here

Comments

Comments are closed.